Evidence map›Paper›PMID 33280173›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2021

2',4'-BNA/LNA with 9-(2-Aminoethoxy)-1,3-diaza-2-oxophenoxazine Efficiently Forms Duplexes and Has Enhanced Enzymatic Resistance*.

Yuki Kishimoto, Osamu Nakagawa, Akane Fujii, Kotaro Yoshioka, Tetsuya Nagata, Takanori Yokota, Yoshiyuki Hari, Satoshi Obika

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yuki KishimotoGraduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka Suita, Osaka, 565-0871, Japan.ORCID http://orcid.org/0000-0001-8556-0178
Osamu NakagawaGraduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka Suita, Osaka, 565-0871, Japan.ORCID http://orcid.org/0000-0001-5412-3530
Akane FujiiGraduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka Suita, Osaka, 565-0871, Japan.ORCID http://orcid.org/0000-0001-6175-4031
Kotaro YoshiokaCore Research for Evolutional Science and Technology (CREST), (Japan) Sciences and Technology Agency (JST), 7 Gobancho, Chiyoda-ku, Tokyo, 102-0076, Japan.
Tetsuya NagataCore Research for Evolutional Science and Technology (CREST), (Japan) Sciences and Technology Agency (JST), 7 Gobancho, Chiyoda-ku, Tokyo, 102-0076, Japan.ORCID http://orcid.org/0000-0003-4111-2693
Takanori YokotaCore Research for Evolutional Science and Technology (CREST), (Japan) Sciences and Technology Agency (JST), 7 Gobancho, Chiyoda-ku, Tokyo, 102-0076, Japan.ORCID http://orcid.org/0000-0002-6490-3263
Yoshiyuki HariFaculty of Pharmaceutical Sciences, Tokushima Bunri University, 180 Nishihamahoji, Yamashiro-cho, Tokushima, 770-8514, Japan.ORCID http://orcid.org/0000-0002-3903-7340
Satoshi ObikaGraduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka Suita, Osaka, 565-0871, Japan.ORCID http://orcid.org/0000-0002-6842-6812
Japan Science and Technology Agency · JPTokyo Medical and Dental University · JPTokushima Bunri University · JP

Funding

Japan Agency for Medical Research and Development JP18am0301004Japan Agency for Medical Research and Development Platform Project for Supporting Drug Discovery and Life Science ResearchJapan Science and Technology Agency Core Research for Evolutional Science and TechnologyJapan Society for the Promotion of Science 15K08024Japan Society for the Promotion of Science 20K05706
6 · The paper itself

Abstract

Artificial nucleic acids are widely used in various technologies, such as nucleic acid therapeutics and DNA nanotechnologies requiring excellent duplex-forming abilities and enhanced nuclease resistance. 2'-O,4'-C-Methylene-bridged nucleic acid/locked nucleic acid (2',4'-BNA/LNA) with 1,3-diaza-2-oxophenoxazine (BNAP (B

Indexed as

Bridged-Ring CompoundsExonucleasesNucleic AcidsOligonucleotidesOxazinesRNA1,3-diaza-2-oxophenoxazineBridged-Ring CompoundsExonucleaseslocked nucleic acidNucleic AcidsOligonucleotidesOxazinesRNAspleen exonucleasebridged nucleic acidsenzyme resistancenucleobasespi interactionssynthesis design

Identifiers

PMID33280173
PMCPMC7898338
OpenAlexW3092786302

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.